Haleon plc
NYSE•HLN
執行長: Mr. Brian James McNamara
板塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
上市日期: 2022-07-25
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
聯絡資訊
The Heights, Building 5, First Floor, Weybridge, KT13 0NY, United Kingdom
44-1932-822000
市值
$43.45B
本益比 (TTM)
31.3
35.5
股息率
2.0%
52周最高
$11.42
52周最低
$8.71
52周範圍
排名34Top 27.8%
4.7
F-Score
改良版 Piotroski 分析
基於 6 年期基本面
一般 • 4.7 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2020-2025
財務儀表板
Q4 2025 數據
營業收入
$7.39B+0.00%
近4季度走勢
每股收益
$0.25+0.00%
近4季度走勢
自由現金流
$1.68B+0.00%
近4季度走勢
2025 Annual 財報亮點
核心亮點
Operating Profit Rises Strongly Operating profit £2.4B, achieving 9.3% growth; Organic operating profit margin reached 10.5% versus 5.0% prior year.
Revenue Declines Slightly Revenue £11.0B, down 1.8% compared to 2024; Basic EPS grew to 18.6p from 15.8p previously reported.
Strong Cash Flow Generation Net cash inflow from operating activities £2.6B; Total borrowings net debt leverage remains stable at 2.6x Adjusted EBITDA.
關注風險
Intense Market Competition Risks Private label growth and consumer preference shifts threaten market share; execution failure risks brand loyalty erosion.
Geopolitical Supply Chain Volatility Geopolitical instability, trade barriers, and inflation increase input costs and disrupt global supply chain operations.
Cyber Security Threat Escalation Increased cyber-attacks risk operational disruption; investment in security culture and technology remains critical focus area.
未來展望
Executing Win As One Strategy Focus remains on delivering growth, productivity, and culture agenda; new operating model expected to yield £175M-£200M savings.
ESG Targets Progress Focus Aiming for 55% Scope 1 and 2 carbon reduction by 2030; committed to reducing virgin plastic use by 50% by 2030.
Shareholder Return Commitment Board proposed 4.9p final dividend; continuation of share buyback programme planned for 2026.
同行對比
營業收入 (TTM)
$244.49B
$129.66B
$30.01B
毛利率 (最新季度)
82.5%
78.3%
68.9%
關鍵指標
股票代碼 | 市值 | 本益比 (TTM) | 股東權益報酬率 (TTM) | 負債率 |
|---|---|---|---|---|
| BDX | $57.44B | 25.7 | 6.9% | 35.6% |
| TAK | $56.30B | 78.1 | 1.6% | 31.5% |
| ZTS | $51.67B | 20.1 | 58.2% | 61.4% |
長期趨勢
近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
1.3%
溫和增長
4季度淨利複合增長率
7.7%
盈利能力逐步提升
現金流穩定性
75%
現金流波動較大
深度研究
下次財報:2026年4月29日
每股收益:$0.25
|營業收入:$7.57B
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表 | 過去12個月 |
|---|
無資料